26th May 2019

****

**Monday 3rd June 2019**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Morning sessions | *Stanmer* *Suite*  **Association of Nephrology Nurses UK** | | *Hall 4*  **NIHR/KRUK industry** | | *Chartwell Suite*  **South of England Kidney Quality Improvement Partnership (KQuIP) Half Day** | | *Ambassador Suite*  **Association of Renal Managers** | | | | | *Preston Suite*  **Renal Society working party imaging session** | | *Queens Suite*  **Paediatric CSG** | | | | *Osborne Suite*  **UK Renal Imaging Network** | | |
| 1100 | **Registration opens** *Sussex Lounge* | | | | | | | | | | **Academic Affairs Committee** *Chartwell Suite*1115-1215 | | | | | | | | | |
| 1130-1245 | *Exhibition Hall*  Lunch and Exhibition | | | | | | | | | | | | | | | | | | | |
| 1130-1230 | *Clarence Suite*  Corporate session - Napp Pharmaceuticals  **Nephrology and the increasing burden of Diabetic Kidney Disease:  Cross Functional Working is Key!**  Dr Robert Lewis, Wessex Kidney Centre, Portsmouth  **Disclaimer**: This promotional symposium has been organised and funded for by Napp Pharmaceuticals Ltd. | | | | | | | | |  | | | | | | | | | | |
| 1245-1400 | *Oxford Suite*  **Plenary Session: Genetics and precision medicine**  Welcome from Graham Lipkin; President of the Renal Association and Sharlene Greenwood, President of the British Renal Society  *The DNA Sequencer will see you now:  lessons from diabetes -* Professor Andrew Hattersley, Professor of Molecular Medicine, Institute of Biomedical and Clinical Science.  *The importance of Genetics for diagnosis and management of rare renal disorders* - Professor Nine Knoers, Clinical Geneticist, Chair of the department of Genetics University Medical Centre Groningen, University Medical Centre Groningen, The Netherlands | | | | | | | | | | | | | | | | | | | |
| 1400-1500 | **RareRenal Meeting** Chartwell Suite | | | | | | | | | | | | | | | | | | | |
| 1410-1540 | *Oxford Suite*  **Three minute heroes** Chair: Mark Dockrell, Carl May and Elaine Davies  16 posters delivered in three minute presentations  Sponsored by Kidney Research UK  49 - *Clinical Practice Guideline: Monitoring children and young people with, and at risk of developing Autosomal Dominant Polycystic Kidney Disease (ADPKD),* Marlais Matko, UCL Great Ormond Street Institute Of Child Health  266 - *The Prepare for Kidney Care Randomised Controlled Trial: Background, Intervention, Outcome Measures and Progress*, Fergus Caskey, University of Bristol  192 - *Randomised Controlled Trial Protocol: The Use of Rituximab In the treatment of Nephrotic Glomerulonephritis (TURING)* – Lisa Wilcocks, Cambridge University Hospitals NHS Foundation Trust  422 - *Assist-HHD Study: A feasibility study Into staff-assisted Home Haemodialysis (aHHD) as an alternative dialysis modality* – Kunaal Kharbanda, Manchester University Hospitals  464 - *Long term outcomes of rituximab treatment in membranous nephropathy* – Aikaterini Nikolopoulou, Imperial College  57 - *Multi-morbidity patterns in patients with non-dialysis chronic kidney disease across England: a multi-centre cluster analysis* – Thomas Wilkinson, University of Leicester  187 - *X-linked Alport syndrome in the genomic medicine era - uncovering unusual clinical phenotypes of COL4A5 variants* – Abhijit Dixit, Nottingham University Hospitals NHS Trust  97 - *Multiparametric Renal MRI to Assess Structure and Function in Chronic Kidney Disease* - Rebecca Noble, The University Of Nottingham  162 - *ABT-263 administration depletes radiation induced senescent cells and reduces renal fibrosis after subsequent injury* – Katie Mylonas, University Of Edinburgh  164 - *Ankyrin Repeat and Single KH domain 1 (ANKHD1) is a novel driver of polycystic kidney disease in vivo* – Maria Fragiadaki, University Of Sheffield  349 - *The role of the calprotectin/ RAGE/ TLR4 axis in ANCA-Associated vasculitis* – Theresa Page, Imperial College  408 - *Vascular endothelial growth factor-C (VEGF-C) reduces cystogenesis in a human cellular model of polycystic kidney disease generated by CRISPR technology* – Nuria Perretta Tejedor, University College London  414 - *Complement in membranous nephropathy* – Aikaterini Nikolopoulou, Imperial College  198 - *Gene polymorphisms associated with microalbuminuria in 396,812 individuals from the UK Biobank cohort* – Marisa Canadas Garre, Queen’s University of Belfast  399 - *JAK2 inhibition halts the growth of polycystic kidney disease-derived epithelial cysts in vitro* – Maria Fragiadaki, University of Sheffield  491 - *The role of GATA3 in bone morphogenetic protein 7 (BMP7) dependent prevention and reversal of myofibroblast phenotype* – Irina Grigorieva, Cardiff University | *Balmoral* *Suite*  **Kidney Transplantation:**  **Recipient, donor, and organ assessment; practical aspects for clinical care** Chair: Nicholas Torpey and Lorna Marson  *Trends and projections for deceased donors and transplants* – Lisa Mumford, Head of ODT Studies, NHSBT  *Expert MDT panel* Professor Lorna Marson, Professor of Transplant Surgery, University of Edinburgh  Dr Menna Clatworthy, Reader in Immunity and Inflammation, NIHR Research Professor, University of Cambridge  Chris Callaghan, Transplant Surgeon, Guy’s and St Thomas, and NHSBT lead for organ utilization  Dr Stephen Marks, Consultant Paediatric Nephrologist, Great Ormond Street Hospital for Children  *The future of donor organ assessment* – Dr Menna Clatworthy  BTS co-badged session | | *Hall 4* The cutting edge of Quality Improvement: tools for kidney care Chair: Ron Cullen and Catherine Stannard *Using structure and finance to drive quality improvement –* DrClara Day, Nephrology Consultant, University Hospitals Birmingham NHS Foundation Trust  *GIRFT: a user’s guide –* Dr William McKane, Consultant Nephrologist, Sheffield Teaching Hospitals NHSFT  *MAGIC: How do we improve cannulation for haemodialysis patients?* – Katie Fielding, Haemodialysis Nurse, University Hospitals of Derby and Burton NHS Foundation Trust  *Using PREM and PROM to drive Quality Improvement –* Rachel Gair, Quality Improvement Programme Manager, UK Renal Registry  **ORAL ABSTRACT PRESENTATIONS**  319 - *Lessons learned from the development and evaluation of a virtual renal clinic* – Sally Hull, Queen Mary University, London  520 - *Introducing a tool to implement Transplant First: Identifying barriers to transplant listing, measuring for improvement, and lessons learned from a pilot centre* – Dr Kerry Tomlinson, University Hospitals North Midlands  442 - *The Kidney Quality Improvement Partnership (KQuIP): Developing and embedding Quality Improvement capability within the kidney community – a local, regional, and national approach* –Rachel Gair, KQuIP | | *Clarence* *Suite*  **“It’s Friday, its 5pm and the phone rings….”** Chair: Marie Condon and Alex Riding    *A young male with pulmonary-renal syndrome – approach to diagnosis and management –* Dr Stephen McAdoo, Consultant Nephrologist, Imperial College London  *Haemolytic anaemia and thrombocytopaenia – what do I do now? –* Dr Edwin Wong, Consultant Nephrologist, National Renal Complement Therapeutics Centre  *A pregnant woman with CKD now with worsening hypertension and proteinuria: management of pre-eclampsia in the woman with CKD –* Dr Katie Bramham, Consultant Nephrologist, King’s Kidney Care / King’s College London | | *Ambassador Suite*  **Future influences on anaemia management in CKD** Chair: Lesley Bennett and Karen Jenkins  *Undertaking research within routine clinical practice:  experiences from the PIVOTAL study*- Alison Blythin, Renal and Research Nurse Specialist, Wessex Kidney Centre  *The PIVOTAL trial: A tipping point in iron management* – Professor David Wheeler, Professor of Kidney Medicine, University College London  *FGF23: At the Intersection of Phosphate and Iron Homeostasis -* Professor Myles Wolf, Duke University School of Medicine.  **ORAL ABSTRACT PRESENTATIONS**  85 - *The effect of initiation of renin-angiotensin system inhibitors on haemoglobin* – George Greenhall, London School of Hygiene and Tropical Medicine  308 - *IV iron dosing and infection risk in the PIVOTAL trial: a pre-specified secondary analysis* – Professor Sunil Bhandari, Hull and East Yorkshire Hospitals NHS Trust  ANSA co-badged session  supported by Pharmacosmos & Kidney Research UK | | | | | *Stanmer* *Suite*  **Renal stone disease, diagnosis and management** Chair: Shabbir Moochala and Stephen Walsh  *Common stone disease – diagnosis and management – Dr* Andrew Connor, Nephrologist, Derriford Hospital, Plymouth  *Rare stone disease – recognition and treatment* – Professor John Sayer, Professor of Renal Medicine, Newcastle University  *A Medical Stone Clinic - Does your unit need one? –* Dr Shabbir Moochhala, Consultant Nephrologist, Royal Free Hospital  **ORAL ABSTRACT PRESENTATIONS**  124 - *Natural history, outcomes and mortality associations of calciphylaxis: Update from the UK calciphylaxis registry* – Rajkumar Chinnadurai, Salford Royal NHS Foundation Trust  25 - *Clinical and biochemical characteristics of hypokalaemic patients: predictors of a genetic diagnosis of Gitelman or Bartter syndrome* – Elizabeth Wan, Royal Free Hospital  31 - *24-hour versus spot urinary sodium and potassium measurements in adult hypertensive patients: a cohort validation study* - Elizabeth Wan, Royal Free Hospital | | *Preston Suite*  **Direct (non vitamin-K) oral anticoagulants (DOACs) in kidney disease**  Chair: Hayley Wells and Sue Shaw    *DOACs – what are they, how are they used, and will they replace* warfarin*? -* Jecko Thachil, Consultant, Manchester Royal Infirmary  *Do we DOAC or Don’t we DOAC? - DOACs in chronic kidney disease (including ESRD), current considerations* *–* Rachna Bedi, Renal Pharmacist  *Atrial Fibrillation in CKD, how should we be using DOACS? -*  Professor Charlie Ferro, Consultant Nephrologist, Queen Elizabeth Hospital  Round table discussion  BRS/RA Education CPD  UK Renal Pharmacy Group  co-badged session | | *Pop-up tent one*  1410-1450  **MOVE - making exercise part of routine care for haemodialysis patients**  Dr Jennifer Cooney, Bangor University  1500-1540  **Useful conversation techniques to develop a good relationship** Ellen Castle and Juliet Mayes, King’s College Hospital London | | | *Pop-up tent two*  1410-1450  **National Nephrology Nursing Course: A Taster Session!**  Nicola Thomas and Helen Hurst, ANNUK/BRS  1500-1520  ***“More Care Less Complexity” – Technological Innovation & Patient Empowerment Finally Coming Together***  Fresenius Medical Care |
| 1540-1610 | *Exhibition* *Hall*  **Tea/Coffee break and Exhibition** | | | | | | | | | | | | | | | | | | | |
| 1610-1710 | *Clarence Suite*  Corporate session – AstraZeneca  **Current and Future Approaches to the Management of Hyperkalaemia**  Dr Kieran McCafferty. Consultant Nephrologist at Barts Health NHS Trust and Senior Lecturer and Queen Mary University London. | | | *Balmoral* *Suite*  Corporate session – Sanofi  **Undiagnosed Renal Disease: Deciphering the Clinical Clues**  Chair: Professor Bruce Hendry  Professor John Sayer, Professor of Renal Medicine, Newcastle University  Dr Shalabh Srivastava,Consultant Nephrologist South Tyneside and Sunderland NHS Foundation Trust & Associate Clinical Lecturer, Newcastle University  Significant number of patients with Chronic Kidney Disease (CKD) will be diagnosed with a rare renal disease each year. However, the diagnostic delay for these patients can be long, lasting for up to 13 years1. This symposium focuses on the importance of unravelling the clinical cues to identify rare renal disease in patients with undiagnosed CKD. Clinical cases will be used to highlight the important role of the nephrologist in recognising the renal signs and symptoms of these rare conditions. Timely diagnosis and treatment remain critical to optimise management and improve outcomes for patients. | | | | | *Hall 4*  **Working together to understand fibrosis and regeneration** Chair: Jamie Davies and Jill Norman  *Assessing the efficacy and safety of cell therapies in preclinical models of kidney* **–** Bettina Wilm, Senior Lecturer, University of Liverpool, Institute of Translational Medicine, Liverpool  *Working together to bridge the gap to translation* **–** Dr Claire Sharpe, Reader in Renal Medicine, King’s College London/King’s College Hospital  *The potential of whole organ MRI and non-invasive assessment of renal fibrosis* **–** Professor Susan Francis, Professor of MR Physics, University of Nottingham  *The patient perspective –* Claire Corps, Patient | | | | | | | *Pop-up tent one*  1610-1650  **Frailty Implications to Practice**  Helen Hurst, Manchester NHS Foundation Trust and Edwina Brown, Imperial College London, Hammersmith  Hospital | | | *Pop-up tent two*  1610-1650  **Optimising recruitment to renal randomised controlled trials**  Leila Rooshenas, University of Bristol | |
| 1715-1745 | *Ambassador Suite*  Highlights of day one | | | | | | | | | | | | | | | | | | | |
| 1745-1900 | *Exhibition Hall*  **Welcome reception and networking in exhibition** | | | | | | | | | | | | | | | | | | | |
| 1800 hours | Fun Run | | | | | | | | | | | | | | | | | | | |
| 1930-2200 | *Clarence Suite*  **Speaker and Committee Dinner** Invitation only | | | | | | | | | | | | | | | | | | | |

**Tuesday 4th June 2019**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 0700 | **Registration opens** | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 0800-0845 | *Clarence Suite*  Corporate session – Alexion  **Establishing a tailored treatment strategy in aHUS – the need for an evidence-based approach**  Professor David Kavanagh, Professor of Complement Therapeutics and Honorary Consultant Nephrologist at the National Renal Complement Therapeutics Centre, Newcastle upon Tyne  Professor Neil Sheerin, Professor of Nephrology at Newcastle University and Consultant Nephrologist at the Freeman Hospital, Newcastle upon Tyne  Please join aHUS expert speakers Prof David Kavanagh and Prof Neil Sheerin, at this Alexion-sponsored symposium, where they will present on challenges related to timely diagnosis of disease, the impact of genetics and the role of the national aHUS service. The symposium will also seek to address the widely-debated topic of the optimal treatment duration in aHUS and the need for an evidence-based strategy that allows for safe withdrawal of treatment in appropriate patients with timely reintroduction in those that relapse. | | | | | | | | | | | | | | | *Balmoral* *Suite*  Corporate session – Otsuka  **JINARC®** Black triangle.**(tolvaptan) for treatment of ADPKD:**  **Refining the identification of eligible patients in early CKD stages and managing long-term outcomes**  **Dr Stewart Lambie, Consultant Nephrologist**, **NHS Highland,** will discuss the rationale for initiating treatment with Jinarc in eligible patients in early disease stages, and how to manage long-term outcomes with regards to kidney function, safety, tolerability and lifestyle adjustments.  **Dr Daniel Gale, Clinician Scientist and Honorary Consultant Nephrologist, Royal Free London NHS Foundation Trust,** will discuss how the patient identification process can be refined, especially in the early CKD stages, by discussing all the available criteria the multidisciplinary team could use to identify patients eligible for treatment with tolvaptan.  The presentations will be supplemented by real-patient case studies to share clinical experience. | | | | | | | | | | | | | | |
| 08.30-10.00 | **Patient Safety Committee meeting** *Chartwell Suite* | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 0850-1000 | *Oxford Suite*  **Plenary Session: Renal Services and Clinical Research Leadership**  Chair: Phil Kalra and Ellen Castle  *A view from the top: kidney care and the long-term plan*  Professor Steve Powis, National Medical Director of NHS England and Professor of Renal Medicine at University College London.  *Mineral Homeostasis in CKD: State of the Art*  Professor Myles Wolf, Professor of Medicine and Chief of the Division of Nephrology at the Duke University School of Medicine. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1000-1030 | *Exhibition Hall*  **Tea/Coffee break and Exhibition** | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1100-1200 | **RareRenal Meeting** *Chartwell Suite* | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1030-1200 | *Oxford Suite*  **Best Clinical and Scientific abstracts** Chair: Gavin Welsh and Alan Salama  Chandos Lecture:  *Reimagining clinical care in ADPKD for the 21st century?* - Professor Albert Ong, Professor of Renal Medicine, University of Sheffield  **ORAL ABSTRACT PRESENTATIONS**  334 - *MinTac: A prospective, multicentre, randomised controlled trial of tacrolimus vs prednisolone for adults with de novo minimal change disease* – Nicholas Medjeral-Thomas, Imperial College  517 - *The impact of utilising the Kidney Failure Risk Equation for referral into secondary care for individuals with chronic kidney disease in the UK* – Dr Harjeet Bhachu, Institute of Applied Health Research, University of Birmingham and Queen Elizabeth Hospital Birmingham  76 - *Physical activity and exercise behaviours of peritoneal dialysis patients in England: results from a multi-centre observational trial* – Courtney Lightfoot, University of Leicester  270 - *A novel small molecule therapy rescues trafficking of misfolded podocin and corrects Nephrotic Syndrome*  *caused by a common podocin mutation* – Valeryia Kuzmuk, University of Bristol  446 - *A novel P2X7 knockout rat is not protected from experimental glomerulonephritis or vasculitis* –Maria Prendecki, Imperial College  229 - *Analysis of intensified immunosuppression response in genetically-stratified steroid resistant nephrotic syndrome (SRNS) patients predicts outcomes and suggests distinct immune mechanisms* – Anna Mason, Bristol Renal, University of Bristol | *Balmoral* *Suite*  **Reproductive health and the kidney** Chair: Liz Lightstone and Lucy Chappell  *My journey with renal disease and pregnancy –* Germin Mohamed, Patient at Hammersmith Hospital, London and Dr Matthew Hall, Consultant Nephrologist, Nottingham University Hospitals  *I have CKD. Can I get pregnant? –* Dr Kate Bramham, Consultant Nephrologist, King’s Kidney Care / King’s College London  *If I do, what will happen to my kidneys?* – Dr Kate Wiles, NIHR Doctoral Research Fellow, St. Thomas' Hospital  *Are my drugs safe?* – Professor Catherine Nelson-Piercy, Professor of Obstetric Medicine, Guy’s & St Thomas’ Foundation Trust and imperial College health care Trust  *Do I have pre-eclampsia or renal disease?* – Professor Lucy Chappell, NIHR Research Professor in Obstetrics  King’s College London  *Q&A time*  Jane Bass  Katherine Clark, Midwife Researcher, King’s College Hospital  BRS/RA Education CPD | *Hall 4*  **BRS/KCUK Research Symposium session**  Chair: Paula Ormandy and Paul Bristow  Donna Lamping Lecture: *Individualising Haemodialysis* – Dr Enric Vilar, Consultant Nephrologist, Lister Hospital  *The management of long-term kidney transplant recipients: MDT Approach -* Dr Antonia Cronin, Consultant Nephrologist, Guy’s Hospital;  *A pilot study on the impact of peer support for people with advanced kidney failure presenting late to renal services -* Eleri Wood, Consultant Nurse, Kings College Hospital  *Patient perspectives of target weight management and ultrafiltration during haemodialysis -* Dr David Keane, Clinical Scientist, St James Hospital, Leeds  *From small beginnings to research impact: How charity-funded projects can directly benefit patients and society, and pave the way for longer and larger grants*  *-* Professor Veronica Swallow, Professor in Child, Young Person and Family Health, University of Leeds | | | | *Clarence Suite*  **UK Renal Trials Network Update: Do you know how to design and interpret a clinical trial?** Chair: Will Herrington and Phil Kalra  *Do you know how to design and interpret a clinical trial? – Dr* Richard Haynes, Associate Professor, University of Oxford  *A Toolkit for Clinical Trials –* Dr Thomas Hiemstra, University Lecturer in Trials, Honorary Consultant Nephrologist University of Cambridge  *How a patient might want to be involved in trial design and conduct –* Dr Claire Corps, Research Scientist, Leeds Teaching Hospitals NHS Trust  *How to analyse and interpret a trial – trial stats made easy –* DrNatalie Staplin, Senior Statistician, University of Oxford  *Recently reported and ongoing renal trials in the UK – a 2019 update –* Fergus Caskey, Consultant senior lecturer, University of Bristol | | | *Ambassador Suite*  **Transplantation: Oral abstracts**  Chair: Caroline Wroe  *AMR focus: UK AMR trial and emerging novel therapies* - Michelle Willicombe,  Imperial College Healthcare NHS Trust  **ORAL ABSTRACT PRESENTATIONS**  368 - *Prophylactic eculizumab treatment significantly improves renal allograft survival in patients with atypical haemolytic uremic syndrome compared with historic controls* – Emily Glover, Newcastle Hospital NHS Foundation Trust  30 - *Healthcare related activity following kidney transplantation* – Eleanor Murray, NHS GGC  158 - *Donor gender and recipient outcomes after kidney transplantation: a population cohort analysis from the United Kingdom* – Georgia Morgan, University of Birmingham  253 - *What mediates socioeconomic inequity in access to living-donor kidney transplantation? Results from a multicentre case-control study* – Pippa Bailey, University of Bristol and North Bristol NHS Trust  522 - *HLA antibody and Tacrolimus variability in transplant recipients during transition from paediatrics to regional adult units* – Shilpa Kaki, Sheffield Kidney Institute  50 - *Barriers to kidney transplantation in children – ATTOMic prospective national study*, Dr Stephen Marks, UCL Great Ormond Street Institute of Child Health  525 - *Correlation between kidney sizes and split renal function in prospective living kidney donors* - Anthony Fenton, University Hospitals Birmingham NHS Foundation Trust | | | | *Stanmer Suite*  **AKI: the role of diagnostics in the development of new therapeutics** Chair: Nick Selby and Andrew Lewington  *AKI biomarkers, where are we now?* – Professor Rosamonde Banks, Professor of Biomedical Proteomics, Leeds Institute of Medical Research at St James’s University of Leeds  *On the Horizon – novel therapeutics for AKI* – Dr Chris Laing  *Epidemiology of paediatric AKI, differences and similarities with adults* – Dr David Milford, Consultant Paediatric Nephrologist, Birmingham Women’s and Children’s Hospital  **ORAL ABSTRACT PRESENTATIONS**  378 - *The Impact of Acute Kidney Injury Requiring Haemodialysis on Patient Survival: 10 years of Prospective Data - An Australian Perspective* – Benjamin Talbot, The George Institute for Global Health  134 - *Long Term Effects of Acute Kidney Injury on Chronic Kidney Disease and Patient Outcomes: 3-year Results from a Large Prospective Parallel Group Cohort Study* – Isma Kazmi, Centre for Kidney Research and Innovation, Derby  316 - *How common is contrast induced acute kidney injury (CI-AKI) in patients undergoing coronary angiography and percutaneous coronary intervention (PCI)?* – Dr Amy Forrester, Frimley Health NHS Foundation Trust | | | | | *Preston Suite*  **Renal hypertension**  **Current evidence, current challenges**  Chair: Rebecca Suckling and Pauline Swift  *Fibromuscular Dysplasia – Rare or Underdiagnosed?* - Dr Tina Chrysochou, Consultant Nephrologist, Salford Royal Hospitals NHS Foundation Trust  *An update on device-based therapy of hypertension* - Dr Vikas Kapil  *New approaches to curing a common cause of Hypertension – Primary Aldosteronism* -Professor Morris Brown, Professor of Endocrine Hypertension, Barts and the London | | | *Osborne Suite*  **TIME to change physical activity, salt and fluid intake behaviours** Chair: Bruno Mafrici and Ellen Castle  *TIME to change behaviour- techniques to assist with behaviour change –* Julie Denning  *Physical activity as a health behaviour in Chronic Kidney Disease –* Dr Pelagia Koufaki, Research Fellow, Centre for Health, Physical Activity and Rehabilitation Research, Queen Margaret University-Edinburgh  *Time to refresh -  an update on Fluid and Salt Management* – Lakshmi Chandrasekharan, Lead Renal & Diabetes Specialist, Southend University Hospital NHS Foundation  **ORAL ABSTRACT PRESENTATIONS**  398 - *Development and implementation of MOVE: making exercise part of routine care for dialysis patients* – Jennifer Cooney, Bangor University  236 - *Self-monitoring of Urine Specific Gravity using Study Smartphone Applications Promotes Adherence to High Water therapy and facilitates remote data capture in the DRINK Randomised Trial* – Ragada El-damanawi, University of Cambridge  Co-badged by the BRS Rehab Network and the Renal Nutrition Group | | | | | *Pop-up tent one*  1030-1110  **“Who asked you?” Exploring Opportunities along your patients journey to empower, enable and co-produce**  Fresenius Medical Care  1120-1200  **Patient Safety: Everybody’s Business**  Katrin Jones, RA/BRS Patient Safety Committee | | | *Pop-up tent two*  1030-1110  **PREM – how units can make the most of their data to inform change – (co-production, QI, collaboration)**  Rachel Gair, Renal Registry  1120-12.00 **Is the treatment of depression an achievable goal?**  Joseph Chilcot, Kings College London |
| 1200-1300 | *Poster Room – Hall 7*  **Moderated Poster Session** | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1200-1300 | **Industry/KQuIP meeting** *Clarence Suite* | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1230-1400 | **RA Working Group on Tolvaptan** *Chartwell Suite* | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1300-1400 | *Exhibition Hall*  **Lunch and Exhibition** | | | | | | | | *Osborne Suite*  **BRS Rehab Network meeting** | | | | *Preston Suite*  **SIMPLIFIED Trial meeting** | | | | | | | *Ambassador Suite*  **UK Living Kidney Donation meeting** | | | | *Stanmer Suite*  **UKKRC glomerulonephritis clinical study group** | | | | | | |
| 1400-1500 | *Clarence Suite*  Corporate Session - Vifor Pharma  **Renal Anaemia – Is it time for change?**  Prof David Wheeler (Chair)  *Professor* of Kidney Medicine at University College London, Honorary Consultant Nephrologist at the Royal Free London NHS Trust.  Prof Chris Probert, Professor of Gastroenterology Cellular and Molecular Physiology, Royal Liverpool Hospital.  **Gut Microbiome and its impact on CKD patients**  Dora Pereira, Researcher and Medical Advisor for Vifor Pharma.  **The science behind irons – are all irons the same?**  Dr Indranil Dasgupta, Consultant Nephrologist, Heartlands Hospital Birmingham.  **The PIVOTAL trial – changing practice.** | | | | | *Balmoral* *Suite*  Corporate Session – Baxter Healthcare Ltd  **Challenging the Status Quo**  **-- Improving Patient Outcome through Innovation**  Dr Clara Day, Consultant Nephrologist, University Hospitals Birmingham NHS Foundation Trust.  Dr Zofia Das-Gupta, ICHOM Standardization Project Leader  Prof Martin Wilkie, Consultant Nephrologist, Sheffield Kidney Institute, Professor of Nephrology, University of Sheffield, Editor in Chief Peritoneal Dialysis International  Prof Sandip Mitra, Senior Consultant Nephrologist  Manchester University NHS Foundation Trust, Honorary  Senior Lecturer, University of Manchester  Mrs. Ann Cole, National Evolving Health Manager, Baxter Healthcare Ltd.  Health outcomes, the results that matter to patients, requires; informed decision-making, quality improvement, innovation and cost reduction. The symposium focuses on ‘Value Based Healthcare’ and the impact of innovation on dialysis patient outcomes /experience. | | | | | | | | | | | *Hall 4*  **Ageing immunity and the kidney** Chair: Alan Salama and Jeremy Hughes  *Determinants of renal ageing* – Professor Paul Shiels, Professor of Geroscience, Institute of Cancer Sciences, MVLS, University of Glasgow  *Immunoscenesence and its management* – Dr Sian Henson, Senior Lecturer, QMUL  *Immunosuppression in older transplant recipients* –Ciara Mgee  240 - *Characterisation of senescent renal epithelial cells in experimental renal disease reveals transcriptional heterogeneity at a single cell level* – Eoin O'Sullivan, University of Edinburgh | | | | | | | | *Pop-up tent one*  1400-1440  **“Being in the Minority”**  Bhavna Pandya, Equal Opportunities in Nephrology Committee of Renal Association  1450-1530  **Optimising recruitment to renal randomised controlled trials**  Leila Rooshenas, University of Bristol | | | | *Pop-up tent two*  1400-1440 **National Nephrology Nursing Course: A Taster Session!**  Nicola Thomas and Helen Hurst, ANNUK/BRS  1450-1530  **The impact of Brexit on kidney care and kidney patients**  Fiona Loud, Kidney Care UK | |
| 1510-1610 | *Oxford Suite*  **NICE RRT Guideline: The Key Issues Debated** Chair: Jan Dudley and Kunaal Kharbanda*Better evidence is needed before recommending high-volume HDF as standard of care: PRO -* Dr James Tattersall, Nephrologist with a special interest in haemodialysis innovation and member of the European Renal Best Practice Guidelines 2000-2019  *Better evidence is needed before recommending high-volume HDF as standard of care: CON* - Dr James Gilbert, Head of Evidence Reviews, National Guideline Alliance (NICE guideline developer), Royal College of Obstetricians and Gynaecologists  *Home therapy should be the default: PRO***–** Professor Jeremy Levy, Consultant Nephrologist, Imperial College Healthcare NHS Trust  *Home therapy should be the default: CON* **–** Dr Andrew Mooney, Consultant Renal Physician and Honorary Clinical Associate Professor, St James's University Hospital | *Balmoral* *Suite*  ***Pregnancy in CKD: Difficult Decisions*** Chair: Kate Bramham and Sue Carr  *Persisting with pregnancy – a good thing? –* Professor Liz Lightstone, Professor of Renal Medicine, Imperial College London  **ORAL ABSTRACT PRESENTATIONS**  484 - *A Study of Maternal and Fetal Outcomes in a Cohort of Pregnant Women with Chronic Kidney Disease* – Nadia Sarween, University Hospitals Birmingham  94 - *Diabetes during pregnancy and congenital genitourinary malformations: A systematic review and meta-analysis* – Mounika Parimi, London School of Hygiene and Tropical Student  129 - *Conception intentions and pregnancy experiences amongst women of childbearing age on dialysis* – Phil Webster, Imperial College Healthcare NHS Trust | | | *Hall 4*  **Kidney Transplantation: improving access, improving outcomes** Chair: Kerry Tomlinson and Graham Lipkin  *Access to transplantation – lessons/findings from ATTOM* – Dr Rommel Ravanan, Consultant Nephrologist, Southmead Hospital  *Understanding and overcoming ethnic barriers to Living Kidney Donation in the UK* – Professor Caroline Wroe, Consultant Nephrologist, South Tees Hospitals NHS Foundation Trust and Dr Katie Wong, Consultant Nephrologist, South Tees Hospitals NHS Foundation Trust  *Combined intelligence: What are we learning from GIRFT and Transplant First Visits?* – Dr William McKane, Consultant Nephrologist, Sheffield Teaching Hospitals NHSFT and Kerry Tomlinson, Consultant Renal Physician, University Hospitals North Midlands | | | | *Clarence Suite*  **Keeping education at the forefront of nephrology training** Chair: Hannah Beckwith and Sue Woodcock  *How can we keep education and training alive in the modern kidney care setting!​ -* Aine Burns, Consultant Nephrologist, Royal Free NHS Foundation Trust  **ORAL ABSTRACT PRESENTATIONS**  91 - *Trainee led development of a national online renal community* – Rhodri Pyart, Cardiff and Vale Health Board  87 - *Inspiring a generation: A Renal Taster Weekend for prospective nephrologists* – Anjali Menon, North Bristol NHS Trust  21 - *Developing an in situ simulation programme on renal emergencies to facilitate improvement in multidisciplinary working* – Ailish Nimmo, NHS Lothian  407 - *Moving towards a risk based model for timing of pre-dialysis planning: our unit’s experience* – Paul Cockwell, University Hospitals Birmingham | | | *Ambassador Suite*  **New drugs for type 2 diabetes – will they protect the heart and the kidneys?**  Chair: Indranil Dasgupta and Richard Haynes  *It’s not just about the sugar – a paradigm shift in the management of type 2 diabetes* – Dr Janaka Karalliedde, Clinical Senior Lecturer and Consultant Diabetologist, King’s College London and Guy’s and St Thomas Hospital  *SGLT2 inhibitors in patients with type 2 diabetes and CKD: Results of the CREDENCE study –* Professor David Wheeler, Professor of Kidney Medicine, University College London | | | | | | *Stanmer Suite*  **Wasting syndromes in CKD** Chair: Tom Wilkinson and Fiona Willingham  *Proposed mechanisms of muscle wasting in CKD and opportunities for therapeutic intervention –* Dr Luke Baker, Post-Doctoral Researcher, University of Leicester  *Screening and diagnosing wasting conditions in CKD –* DrClare McKeaveney, Research Fellow, University of Belfast  **ORAL ABSTRACT PRESENTATIONS**  244 - *A programme of supervised exercise and multidisciplinary education (PREHAB) prevents deterioration in physical function and nutritional status in persons approaching and commencing dialysis* – Fiona Willingham, University Hospitals of Derby and Burton NHS Foundation Trust  375 - *CKD-PAQ: Developing a tool for physical activity estimation in chronic kidney disease* – Sivakumar Sridharan, Lister Hospital  Co-badged by the BRS Rehab Network and the Renal Nutrition Group | | | *Preston Suite*  **Polycystic kidney disease: from mechanisms to personalised management** Chair: John Sayer and Maria Fragiadaki  *From ADPKD cell biology to prediction of clinical progression via urinary exosomal biomarker profiling* – Professor Patricia Wilson, Professor Renal Medicine, UCL/Royal Free  *Advantages of using a genetic testing to predict the risk of disease progression in ADPKD* – Dr Emilie Cornec-Le Gall, Associate Professor in Nephrology, Nephrology Brest University Hospital and INSERM 1078  *Challenges of using imaging to predict the risk of progression in the UK* – Dr Roslyn Simms, Consultant Nephrologist & Honorary Senior Lecturer in Nephrology, Sheffield Kidney Institute, Northern General Hospital & University of Sheffield | | *Osborne Suite*  **Electronic Patient Reported Outcomes (ePROs) – state of the art** Chair: Rachel Gair and Nicola Anderson  *Symptom monitoring in advanced chronic kidney disease using electronic patient-reported outcomes –* Dr Derek Kyte, Lecturer in Health Research Methods, University of Birmingham  *Towards national collection of ePROs as part of renal services in the UK* *–* Sabine van der Veer, Lecturer in Health Data Science, University of Manchester  **ORAL ABSTRACT PRESENTATIONS**  18 - *Poor advance care planning in older patients with end-stage renal disease: a qualitative interview study of nephrologists* – Andrew Smyth, Galway University Hospital and Clinical Research Facility at the National University of Ireland, Galway  329 – *Longitudinal effects of depression on cognitive function in haemodialysis patients* – Aghogho Odudu, University of Manchester | | | | | *Pop-up tent one*  1540-1620 **Introduction to ANNUK Home Haemodialysis Special Interest Group**  Carol Rhodes, Janet Walker, ANN UK | | |
| 1600-1700 | **Academic Affairs Meeting** *Chartwell Suite* | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1610-1650 | **Exhibition**  **Tea/Coffee break and Exhibition** | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1650-1820 | *Balmoral* *Suite*  **Transformational leadership – Examples from practice, Individual to organisational level**  Chair: Marissa Dainton and Karen Jenkins  *Jane MacDonald leadership lecture* – *Renal research in the UK: stimulating participation, facilitating careers’* -Professor Philip Kalra, Consultant Nephrologist at Salford Royal Hospital, Professor at the University of Manchester.  *The National Picture and presentation of work across professional disciplines to improve patient outcomes using transformational leadership* – Professor Kim Manley, Professor Practice Development, research and Innovation, England Centre for Practice Development, Canterbury Christ Church University & East Kent Hospitals University NHS Foundation Trust  *Making an Impact on Nursing recruitment and retention* – Claire Main, Lead Nurse for Nephrology and Transplant, University Hospital of Wales, Cardiff  *From HCA to ANP a journey that can be replicated!* Victoria Ashworth Advanced Nurse Practitioner Royal Liverpool Hospitals (Video)  *From Health Care Support Worker to National Leader – A personal and service transformational journey focussed on improving the quality of life for people receiving haemodialysis* -  Gail Williams, Renal Nurse of the Year*,* Lead Nurse Welsh Renal Clinical Network, Welsh Health Specialist Services Committee  Co-badged by ANNUK | *Hall 4*  **Advances in PD: From basic science to patient experience** Chair: Neil Sheerin and Linsey Worsey  *Understanding the peritoneal immune system in peritoneal dialysis*- Chia Te Liao, Kidney Research UK fellow, Wales Kidney Research Unit, Cardiff University  *De Wardener Lecture – Individualising the peritoneal dialysis prescription -* Professor Edwina Brown, Consultant, Hammersmith Hospital  *Transitioning from PD to HD: patient and carer experiences* – Kim Stein  *Impact of clinical practice patterns: Results from P-DOPPS* – Dr Mark Lambie, Senior Lecturer and Honorary Consultant in Renal Medicine, Royal Stoke University Hospital  **ORAL ABSTRACT PRESENTATIONS**  117- *Innate immune response biomarkers in peritoneal dialysis effluent as reliable diagnostic indicators of peritonitis - evaluation of a rapid diagnostic test device* – Cate Goodlad, Royal Free Hospital | | *Clarence Suite*  **Multimorbidity and kidney disease – impact and implications** Chair: Simon Fraser and Kristin Veighey  *Chronic Kidney Disease, multimorbidity and inequalities* **–** Professor Paul Roderick  *The impact of multimorbidity on Acute Kidney Injury*– Dr Lynne Sykes, Clinical Research Fellow, Salford Royal Foundation Hospital  *Treatment burden and minimally disruptive medicine for people with kidney disease* **–** Professor Frances Mair, Norie Miller Professor of General Practice and Head of General Practice and Primary Care, Institute of Health and Wellbeing, University of Glasgow  **ORAL ABSTRACT PRESENTATIONS**  388 - *The Electronic Frailty Index (eFI) Indicates Mortality Risk in End Stage Kidney Disease (ESKD) Patients on Dialysis* – Andrew Mooney, St James’s University Hospital  108 - *Temporal trends in prevalence of chronic kidney disease in England: comparison of nationally representative cross-sectional surveys from 2003 to 2016* – Hilda Hounkpatin, University of Southampton  212 - *Prognostic accuracy of frailty screening methods in advanced chronic kidney disease* – Andrew Nixon, Lancashire Teaching Hospitals NHS Foundation Trust  *Sponsored by Kidney Research UK* | | | | *Ambassador Suite*  **Implementing more or less; the challenges of the non-standard haemodialysis schedule** Chair: James Burton and Enric Vilar  *Blue sky thinking and dialysis provision: why it’s important to patients* - Maddy Warren, Dialysis Patient  *Implementing more or less; the challenges of non-standard haemodialysis* – Dr Raja M Kaja Kamal, Renal Research Registrar, Lister Hospital  *Mind the gap: the problem with three times a week in-centre haemodialysis* – Dr James Fotheringham, Consultant Nephrologist, Sheffield Kidney Institute  *Doing things differently: the hospital perspective* - Suzi Glover, Deputy Head of Nursing, Leicester Hospitals  *Panel Q&A.*  **ORAL ABSTRACT PRESENTATIONS**  453 - *The effect of centre practice in initiating haemodialysis by an incremental approach compared to standard practice and short term patient survival* – Andrew Davenport, Royal Free Hospital  518 - *Acceptability of alternate day dialysis regimes to patients on in-centre maintenance dialysis: a multi-centre survey* – Enric Vilar, Eastern North Herts NHS Foundation Trust  267 - *Feasibility of non-contrast cardiac MR stress T1-mapping to assess coronary artery disease in patients on haemodialysis* – Federica Poli, University of Leicester | | | *Stanmner* *Suite*  **Long-term kidney transplant follow up: A Multidisciplinary approach**  Chair: Antonia Cronin and Eleri Wood  *Developing a long-term kidney transplant assessment and review clinic: Challenges and Triumphs -* Ms Sharon Frame, Clinical Nurse Specialist, Guys and St Thomas NHS Trust  *Cardiovascular disease in long-term kidney transplant recipients -* Dr Adnan Sharif, Consultant Nephrologist Queen Elizabeth University Hospital Birmingham  *Non-melanoma skin cancer in long-term kidney transplant recipients: Prevalence and prevention -* Dr Mary Wain, Consultant Dermatologist, St. John’s Institute of Dermatology, Guy’s and St. Thomas’ NHS Foundation Trust, London  *Bone Disease after Transplantation* - Dr Arif Khwaja, Consultant Physician Sheffield Kidney Institute  *Medication Adherence in long-term kidney**transplant recipients* **-**Hayley Wells, Senior Renal Pharmacist, Guy’s and St. Thomas’ NHS Foundation Trust, London | | | | *Preston Suite*  **How can routinely collected data improve kidney care?** Chair: Dorothea Nitsch and Elizabeth Wallin  *Changes in creatinine after starting RAS blockade: A matter of perspective? –* Dr Laurie Tomlinson, Associate Professor/Honorary Consultant Nephrologist, London School of Hygiene and Tropical Medicine  *Are bisphosphonates safe in CKD? –* Professor Dani Prieto-Alhambra  *What does observational research tell us about AKI care?* – Dr Simon Sawhney, Clinical Lecturer, University of Aberdeen  **ORAL ABSTRACT PRESENTATIONS**  67 - *Outcomes in the first 90 days after starting dialysis – transition of the UK Renal Registry to capture of all acute and chronic dialysis sessions* – Barnaby Hole, UK Renal Registry  474 - *Heart failure and AKI after hospital admission with AKI among patients taking ACE inhibitors and ARBs* – Patrick Bidulka, London School of Hygiene and Tropical Medicine  248 - *A model of cardiovascular disease in people with reduced renal function using routine healthcare data* – Claire Simons, University of Oxford | | | | | *Osborne Suite*  **Monoclonal gammopathy of renal significance (MRGS), amyloidosis and multiple myeloma: recent advances** Chair: Jennifer Pinney and Julian Gillmore  *Recent Developments in Monoclonal Gammopathy of Renal Significance and Myeloma and the Kidney*  *-* Professor Paul Cockwell, Consultant Nephrologist, University Hospital Birmingham  *Histopathology of paraprotein-related kidney diseases* - Dr Candice Roufosse, Senior Clinical Lecturer Imperial College  *What the nephrologist needs to know about current and new treatments for MGRS, amyloid and myeloma* – Professor Ashutosh Wechalekar, Consultant Haematologist, National Amyloidosis Centre, UCL  **ORAL ABSTRACT PRESENTATIONS**  286 - *Renal Outcome in Patients with Newly Diagnosed Multiple Myeloma: Results from the UK NCRI Myeloma XI trial* – Ritika Rana, Queen Elizabeth Hospital Birmingham  367 - *Proliferative glomerulonephritis with non-organised monoclonal immunoglobulin deposits (PGNMID): a single-centre retrospective study* – Sarah Blakey, Imperial College NHS Trust  478 - *Association between non-malignant monoclonal gammopathy and risk of adverse outcomes in chronic kidney disease* – Anthony Fenton, University Hospital Birmingham | | *Buckingham Suite*  **Vascular Disease and the Kidney** Chair:  *Endothelial responses to mechanical shear stress –* Professor Paul Evans, Professor of Cardiovascular, University of Sheffield  *Role of the innate immune system in hypertension & its complications –* Neeraj Dhaun (Bean), Senior Lecturer in Nephrology & Honorary Consultant Nephrologist, University of Edinburgh  *CKD, Inflammaging and vascular calcification*  – Professor Catherine Shanahan, Professor, King’s College London  *Early intervention to prevent microvascular dysfunction of the kidney* – Dr Becky Foster, Senior Lecturer, University of Bristol  **ORAL ABSTRACT PRESENTATIONS**  445 - Using three-*dimensional imaging to study how kidney lymphatic vessels develop* – David Long, Great Ormond Street Institute of Child Health | | | | *Pop-up tent one*  1650-1730  **How can the NIHR In-Vitro Diagnositic Co-Operatives Support the Development and Introduction of New**  **Diagnostics for Kidney Disease?** Dr Andrew Lewington, Consultant Renal Physician/Honorary Clinical Associate Professor, Associate Director NIHR Leeds In-Vitro Diagnostic Co-operative,  St. James’s University Hospital  1740-1820  **Physical activity, energy, nutrition and understanding laboratory parameters in** **chronic kidney disease (ckd)**  **patients – pilot findings following an educational webinar via a social media platform**  Shahid Muhammad, The University of West England  Wednesday | | | | *Pop-up tent two*  1650-1730  **The Southwest approach to KQuiP – delivering transplant first in this region involving the multi professional team alongside patients** Rachel Gair, KQuiP  1740-1820 **“Being in the Minority”** Bhavna Pandya, Equal Opportunities in Nephrology Committee of Renal Association |
| 1825-1905 | *Ambassador Suite*  Highlights of Day Two | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1905-1940 | SpR Club drinks reception for Junior Doctors *Clarence Suite* | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1940 | **Pre-dinner drinks, followed by conference Dinner** *Oxford Gallery* | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

**Wednesday 5th June 2019**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 0745 | Sussex Lounge  **Registration Opens** | | | | | | | | | | | | | | | | | | | | | |
| 0745-0845 | *Osbourne Suite*  Renal Association AGM | | | | | | | | | | | | | | | | | | | | | |
| 0845-1000 | *Oxford Suite*  **Plenary Session: Delivering the best care to the most vulnerable**  Chair: Graham Lipkin and Maarten Taal  *End of life care in chronic disease: Lessons for the kidney care community*  Baroness Ilora Finlay, Professor of Palliative Medicine at Cardiff University and Independent Crossbench member of the House of Lords  ***Raine Lecture*** -  *The psychosocial health of young adults on renal replacement therapy-*  Dr Alexander Hamilton, Clinical Lecturer in Renal Medicine, University of Bristol/North Bristol NHS Trust  ***Mallick Lecture*** –  *Upstream to the Reservoir* - Karen Jenkins, Consultant Nurse, Kent Kidney Care Centre | | | | | | | | | | | | | | | | | | | | | |
| 1000-1030 | **Tea/Coffee break and Exhibition** *Exhibition Hall* | | | | | | | | | | | | | | | **RareRenal meeting** *Chartwell Suite*1000-1100 | | | | | | |
| 1100-1200 | **RA Education and Training meeting** *Chartwell Suite* | | | | | | | | | | | | | | | | | | | | | |
| 1030-1200 | *Oxford Suite*  **Living well with frailty and CKD** Chair: Helen Hurst and Andrew Nixon  *What is frailty and why is it important for renal medicine? –* Dr Andrew Nixon, Clinical Research Fellow in Renal Medicine, Lancashire Teaching Hospitals NHS Foundation Trust  *What is the Comprehensive Geriatric Assessment and how can it benefit patients with CKD?* - Dr David Hunt  *Falls and rehabilitation for patients living with frailty and CKD* - Hannah Young, Senior Physiotherapist, NIHR Doctoral Research Fellow, University Hospitals of Leicester /University of Leicester  *Cognition and CKD: Should we be doing more?* - Dr James Tollitt, Renal Research Fellow, Salford Royal NHS Foundation Trust  *Putting it into practice –* Professor Edwina Brown, Consultant, Hammersmith Hospital  Panel Discussion  BRS/RA Education CPD | *Balmoral Suite*  **Quality Improvement – the best of the best from the UK kidney community** Chair: Elizabeth Wallinand Leeanne Lockley  *What does a successful Quality Improvement project look like? Lessons from the front line* – Dr Amanda Newnham, Consultant Paediatric Nephrologist, Leeds Children’s Hospital  **Launch of the National Standards for Transport for Patients receiving Haemodialysis**  **ORAL ABSTRACT PRESENTATIONS**  486 - *Wide variance in transport provision for patients receiving in centre or satellite haemodialysis treatment in the UK: results of a national survey* – Paul Cockwell, Queen Elizabeth Hospital Birmingham  494 - *Standards for Transport Provision for Patients receiving in centre or satellite unit haemodialysis: Finding a Way Together* – Fiona Loud, Kidney Care UK  439 - *A paediatric AKI service: Improving recognition and reducing incidence* – Grace McCall, Manchester University Hospitals  113 - *Acute Kidney Disease - a new definition, but is it useful in describing renal outcomes following AKI?* – Isma Kazmi, Centre for Kidney Research and Innovation, Derby  454 - *Partnership working to provide bespoke renal welfare and debt management service* – Dr Jack Bramhall University Hospitals Birmingham NHS Foundation Trust  381 - *Increasing the prevalence of shared haemodialysis care at Salford Royal Foundation Trust dialysis units* – Emma Jenner, Salford Royal Foundation Trust  82 - *Reducing inpatient admissions by ambulating care for patients with acute kidney injury (AKI)* – Nicholas Annear, St George's University Hospitals NHS Foundation Trust | | *Hall 4*  **Vascular access: current challenges, future solutions** Chair: Saeed Ahmed and Paul Gibbs  *Interventional Nephrology training my experience* - Dr Rauri Clark, Consultant Nephrologist, City Hospitals of Sunderland  *Should Nephrologist do Fistuloplasty?* - Dr David Lewis, Consultant Nephrologist, Salford Royal NHS Foundation Trust  *What the UK can learn from ASDIN* - Professor Asif Arif, Chair: Department of Medicine, Professor of Medicine, Jersey Shore University Medical Center    *The Surfacer for Access – Use in Central Vein Occlusion*- James Gilbert, Consultant Transplant & Vascular Access Surgeon, Vascular Access Lead Training Programme Director Core Surgery HETV Oxford Transplant Centre  *Update on DCB use in the AV Access circuit* – Dr Kate Steiner, Consultant Interventional Radiologist, East and North Herts NHST  *Update on EndoAVFs in the UK and Wider World* - Dr. Aurang Zaib Khawaja, Department of Renal transplant surgery and dialysis access | | | *Clarence Suite*  **Patient involvement in service provision, quality improvement and research** Chair: Nicola Thomas and Paul Bristow  *Patient involvement - why is it so important*– Simon Denegri OBE, NIHR National Director for Patients, Carers and the Public  *Kidney Community Patient Involvement quality standards: results of the NIHR INVOLVE Test bed project –* Professor Paula Ormandy, Professor Long Term Conditions Research / British Renal Society Vice President Research, University of Salford and Mr David Coyle  *Getting it right first time – the reality of meaningful patient and public involvement* – Professor Nicki Thomas, Professor of Kidney Care, London South Bank University  **ORAL ABSTRACT PRESENTATIONS**  370 - *Do clinical staff activate patients? The relationship between Clinician Support for Patient Activation and the Patient Activation Measure in In-centre haemodialysis patients* – Maria Keriakos, Sheffield Kidney Institute  417 - *What information do staff use to involve patients in decisions about conservative management? A critical review of leaflets used in UK renal services* – Anna Winterbottom, Leeds Teaching Hospitals  53 - *Co-producing progression criteria for feasibility studies: a partnership between patient representatives, clinicians and researchers* – Hannah Young, Senior Physiotherapist, NIHR Doctoral Research Fellow, University Hospitals of Leicester /University of Leicester | | | *Ambassador Suite*  **Equal opportunities and diversity** Chair: Rebecca Suckling and Claire Sharpe  *Equal opportunities in Nephrology (EON) UK survey findings -*Dr Bhavna K Pandya, Chair EON committee RA, Consultant Nephrologist Aintree University Hospital NHS Foundation Trust  *LTFT working and addressing the gender pay* – Sally Brett, Head of Equality, Inclusion and Culture, British Medical Association  *Equality & Diversity – a Personal Perspective* - Professor Rajiv Hanspal, Retired Consultant in Rehabilitation Medicine  Round table discussions facilitated by Baroness Ilora Finlay, Professor of Palliative Medicine at Cardiff University and Independent Crossbench member of the House of Lords | | *Stanmer Suite*  **Diabetic nephropathy from inflammation to fibrosis** Chair: Becky Foster and Indranil Dasgupta    *Targeting the glomerular vasculature as a treatment for diabetic nephropathy* – Professor Luigi Gnudi, Professor of Diabetes and Metabolic Medicine, School of Cardiovascular Medicine & Science, King’s College London and Guy’s and St Thomas NHS Foundation Trust  *Transglutaminase 2: A therapeutic target in renal fibrosis* – Professor Tim Johnson, Director Fibrotic Remodelling, UCB Biopharma  *What is new with the podocyte and diabetes?* – Professor Richard Coward, Professor of Renal Medicine, Bristol University and Consultant Paediatric Nephrologist.  **ORAL ABSTRACT PRESENTATIONS**  415 – *The functional consequences of myocardial fibrosis in chronic kidney disease* – Manvir Hayer, University Hospitals Birmingham  156 - *A novel heparanase inhibitor protects glomerular endothelial glycocalyx during diabetes mellitus* – Monica Gamez, The University of Bristol  512 - *Identification of high-risk patient clusters based on extracellular matrix turnover* – Paul Cockwell, Queen Elizabeth Hospital Birmingham | | | *Preston Suite*  **Glomerulonephritis abstracts** Chair: Ruth Pepper  **ORAL ABSTRACT PRESENTATIONS**  341 - *Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis – A randomised controlled trial* – Aikaterini Nikolopoulou, Imperial College Healthcare NHS  497 - *Long-term follow up of a steroid-minimising regimen for remission-induction in ANCA associated vasculitis* – Dr Stephen McAdoo, Consultant Nephrologist, Imperial College London  449 - *The effect of P2X7 antagonism on nephrotoxic nephritis* – Maria Prendecki, Imperial College  359 - *Live glomerular imaging in experimental crescentic glomerulonephritis reveals sequential glomerular infiltration of monocyte subsets with distinct effector functions* – Tabitha Turner-Stokes, Imperial College  389 - *Chorioretinal thickness tracks disease activity in clinical ANCA vasculitis* **–** Tariq Farrah, University of Edinburgh  215 - *Histological findings in acute interstitial nephritis – a role for scoring non-fibrotic inflammation* – Emma Cannon, Queen Elizabeth University Hospital, Glasgow  325 - *Myeloperoxidase inhibition: potential therapeutic target for crescentic glomerulonephritis?* – Marilina Antonelou, University College London  495 - *Fostamatinib treatment of a new model of MPO-ANCA vasculitis in WKY rats induced by administration of a sub-nephritogenic dose of nephrotoxic serum after immunisation with human myeloperoxidase* – Stephen McAdoo, Imperial College London  242 - *Signalling Response Under Par: A PAR-1 mediated signalling pathway in podocytes is a consistent feature of ‘circulating factor’ initiated nephrotic syndrome* – Carl May, Bristol Renal | | | | *Pop-up tent one*  1030-1110  **Is the treatment of depression an achievable goal?**  Joseph Chilcot, King’s College London  1120-1200  **Let us spice it up! The low potassium diet for African-Caribbean, south Asian, Far Eastern and Eastern European**  **cultures**  Deepa Kariyawasam, British Dietetic Association Renal Nutrition Group | | | *Pop-up tent two*  1030-1110  **Useful conversation techniques to develop a good relationship**  Ellen Castle and Juliet Mayes, King’s College Hospital London  1120-1200  **Developing resilience in the renal service**  Amanda Bevin, RPT |
| 1200-1300 | **RA Research meeting** *Chartwell Suite* | | | | | | | | | | | | | | | | | | | | | |
| 1210-1310 | *Clarence Suite*  Corporate Session - Pharma Vifor  **Systematic Approaches to Managing Hyperkalaemia**  Chair: Prof Phil Kalra  Dr Kieran McCafferty, Consultant Nephrologist, Barts Health NHS Trust.  Dr Chris Wong, Consultant Nephrologist, Aintree University Hospital NHS Trust. | | | | *Balmoral* *Suite*  Corporate Session – Syner Med  **Developments in vascular access practice in challenging haemodialysis patients**  Chair and Speaker – Dr Mick Kumwenda, Consultant Nephrologist, Glan Clwyd Hospital, Rhyl  Mr Paul Gibbs, Consultant Vascular Access and Transplant Surgeon, Wessex Kidney Centre, Queen Alexandra Hospital, Portsmouth.  President of VASBI.  Margaret Aitken, Vascular Access Clinical Nurse Specialist, Queen Elizabeth Hospital, Glasgow  Chair: VASBI Nurses Section, Co-Chair: MAGIC  Vascular access is crucial for successful haemodialysis and is prone to thrombosis, which if untreated results in failure. This session is aimed at sharing best practice of managing vascular access patency and the growing interest in using lower limb grafts where autogenous venous access is no longer a viable option. Findings of a multicentre prospective audit of Syner-KINASE® (Urokinase) used to restore patency in occluded central venous catheters and the first evidence based protocol will also be presented. | | | | | | | | *Hall 4*  **Mechanisms of tubulointerstitial injury** Chair: Patricia Wilson and Heather Wilson  *The collecting duct: A critical protector against renal tubulointerstitial injury?* - Dr Qihe Xu, Senior Lecturer in Renal Medicine, King's College London  *Collecting duct contribution to development, injury and repair* - Dr Joan Li, Senior Researcher, Lecturer, University of Queensland | | | | *Pop-up tent one*  1210-1250  **Advanced Care Planning; How it can be used in practice**  Helen Hurst, ANNUK and Margaret Eyre, Renal Social Work Group | | | *Pop-up tent two*  1210-1250  **National Nephrology Nursing Course: A Taster Session!**  Nicola Thomas, ANNUK | | |
| 1310-1410 | **Lunch & Exhibition** *Exhibition Hall* | | | | | | | **TURING Investigator meeting** *Chartwell Suite*  1325-1410 | | | | | | | **RA International meeting** *Chartwell Suite*  *1410-1510* | | | | | | | |
| 1410-1510 | *Poster Room – Hall 7*  **Moderated Poster Session** | | | | | | | | | | | | | | | | | | | | | |
| 1510-1610 | **RA Patient Info meeting** *Chartwell Suite* | | | | | | | | | | | | | | | | | | | | | |
| 1515-1615 | *Oxford Suite*  **Crouching Tiger– Hidden trauma Hidden Psychological Trauma in Renal Patients- Its’ relevance and its’ treatment** Chair: Siobhan Commins and Gillian Chumbley  *Exploring Early Trauma in Altruistic Donors* - Angela Taylor - Lead Specialist Renal Counsellor, Brighton and Sussex University Hospitals NHS Trust  *EMDR a Psychological Trauma Intervention in the Renal Setting*  – Maria Tribe, Renal Psychotherapist and Counsellor, Brighton and Sussex University Hospitals NHS Trust and Jane Sudlow - Specialist Renal Psychotherapist/Counsellor Brighton and Sussex University Hospitals NHS Trust  *AKI King’s counselling service –* Juliet Davies - Senior counsellor & psychotherapist,  Kings College Hospital | *Balmoral Suite*  **Improving the management of AKI for the population** Chair: Nicholas Selbyand Marissa Dainton  *Welcome and opening* - Dr Nick Selby, Consultant Nephrologist, Derby Hospitals NHS Foundation Trust  *Data and linking data – changes in practice leading to changes in outcomes*  *CCG reporting update*  *GIRFT using AKI data*  *What comes out of the AKI analysis over the next three months*  *HES linkage* - James Medcalf, Consultant Nephrologist, John Walls Renal Unit, Leicester  *RCGP AKI Project –* Dr Jon Murray, Consultant Nephrologist, James Cook University Hospital, Middlesbrough and Dr Tom Blakeman, GP and Clinical Senior Lecturer in Primary Care, University of Manchester  *Linking with other work – TAKI, NW, other improvement initiatives*  *Educational package and care patterns* - Dr Nick Selby, Consultant Nephrologist, Derby Hospitals NHS Foundation Trust  *Q&A discussion panel* - Dr Nick Selby, Consultant Nephrologist, Derby Hospitals NHS Foundation Trust | *Hall 4*  **Strategies to influence gut microbiota imbalance and its importance in kidney disease** Chair: Fiona Willingham and Dan March  *The gut microbiome in CKD: friend or foe? –* Dr Bjorn Meijers, Consultant Nephrologist, Leuven, Belgium  **ORAL ABSTRACT PRESENTATIONS**  167 - *Comparing active lifestyle intervention using renal dietician-led behaviour change techniques versus standard of care after kidney transplantation (CAVIAR): a randomised controlled trial* – Kulli Kuningas, University Hospitals Birmingham  12 - *Skin autofluorescence and malnutrition as predictors of mortality in dialysis patients* – Daniela Viramontes Horner, University of Nottingham  Renal Nutrition Group Co-badged Session | | | *Clarence Suite*  **Clinico-Pathological Correlation**  **Linking clinical disease, pathology, and treatment** Chair: Nicholas Torpey and Ailish Nimmo  *The* *pitfalls of premature diagnostic closure* - Dr Nina Gerdes, Post CCT Fellow, Lister Hospital, East and North Hertfordshire NHS Trust and Dr Barbara Thompson, Consultant Nephrologist, East and North Herts NHS Trust  **ORAL ABSTRACT PRESENTATIONS**  79 - *Focal segmental necrotising glomerulonephritis associated with selective IgA deficiency: two case reports* – Madelena Stauss, Royal Preston Hospital, Lancashire Teaching Hospitals  528 - *An Unusual Infiltrative Cause of Acute-on-Chronic Kidney Injury* – Hugh Leonard, Guy’s and St Thomas’  Pathology presented by Professor Terry Cook | | | *Ambassador Suite*  **Supporting the development of nephrology in low and middle income countries** Chair: Jennie Jewitt-Harris and Iain MacPhee  *The ISN Sister Renal Centres Experience in Bosnia -* Dr Aimn Ahmed, Consultant Nephrologist and Hon. Senior Lecturer,  Lancashire Teaching Hospitals NHS Foundation Trust/Manchester University  *Experiences of kidney disease in Malawi* - Dr Gavin Dreyer, Consultant, Whipps Cross Hospital  *Experience in India -* Dr Debasish Banerjee, Consultant Nephrologist St Georges University Hospital NHS Foundation Trust | | *Stanmer Suite*  **Late breaking abstracts and taking evidence into clinical practice**  Chair: Paul Cockwell and Alex Riding  536 – *Comparative effects of oral anti-diabetic agents after metformin monotherapy in UK primary care: a propensity-score matched cohort study* – Laurie Tomlinson, London School of Hygiene and Tropical Medicine  545 – *A study of Factors AssoCiated with Treatment Resistant HYpertension (FACT-RHY): a description of phenotypical, physiological and biochemical characteristics of patients with true treatment-resistant hypertension compared to treated patients with hypertension* - Mohammed Hameed, UHCW  541 - *CYCLE-HD: Improving cardiovascular health in patients with end stage renal disease using a structured programme of exercise. A randomised controlled trial* – James Burton, University of Leicester  CREDENCE, PIVOTAL: taking evidence into clinical practice - Dr Alex Riding, ST5 Renal Medicine, East and North Herts NHS Trust, East of England  Panel Discussion  Sharlene Greenwood, Consultant Physiotherapist in Renal and Exercise Rehabilitation, NIHR Postdoctoral Research Fellow  King's College Hospital  Dr William Herrington, Medical Research Council Population Health Research Unit, University of Oxford  Fiona Loud, Policy Director, Kidney Care UK  Dr Asheesh Sharma Consultant Nephrologist,  Royal Liverpool University Hospital | | | *Preston Suite*  **Epigenetic regulation in kidney disease** Chair: Timothy Bowen and Moin Saleem  *Dynamics of DNA promoter methylation in progression of chronic kidney disease* – Professor Michael Zeisberg  *The relevance of CD44 alternative splicing in the regulation of pro-fibrotic and anti-fibrotic cell functions in CKD* – Dr Soma Meran  **ORAL ABSTRACT PRESENTATIONS**  \*\*423 - *RNA regulation in renal disease: mutations in the ribonucleoproteins dyskerin and NOP10 are associated with a novel nephrotic syndrome* – Jennie Chandler, Great Ormond Street Institute of Child Health **\*\***  241 - *Adeno-Associated Virus Vector Gene Therapy Ameliorates Nephrosis in a Podocin-deficient Mouse Model of Nephrotic Syndrome* – Wen Yi Ding, University of Bristol  ***\*\*Abstract 423 was the highest scoring abstract of the conference*** | | | | *Pop-up tent one*  *1515-1555*  ***Latest application of Home HD: from patients’ outcomes to environmental benefits in the UK***  NxStage Medical | | | ***Take column out please*** | |
| 1620-1650 | *Oxford Suite*  **Plenary Session: From Bench to Bedside and the Best of Brighton 2019!**  Chair: Donal O’Donoghue and Andrew Mooney  *A special finale: Professor Charles Pusey - a Lifetime in vasculitis research (Osman Lecture 2019)* - Professor of Medicine, and Head of the Renal Section in the Department of Medicine, Imperial College London. | | | | | | | | | | | | | | | | | | | | | |
| 1650-1730 | *Oxford Suite*  Highlights of the day and conference close | | | | | | | | | | | | | | | | | | | | | |
| 1700 | *Sussex Lounge*  Tea/Coffee (with take away cups available) | | | | | | | | | | | | | | | | | | | | | |

\**“This meeting has been supported by Chiesi Limited through purchase of exhibition stand space only, with no input into the agenda”*